#ASH18 – Coming to a Close

Teresa Miceli |

The American Society of Hematology (#ASH18) annual meeting is has come to an end. Monday has been traditionally known as “Myeloma Madness Monday.” This year was no different. Oral sessions included topics on the combination therapies, #CAR-T and #BiTE (Bispecific T-cell Engager) therapy. Other potential new agents in #myeloma, like venetoclax, selinexor and isatuximab, were […]

ASH 2018: Overwhelming But Enriching

Valarie Traynham |

ASH 2018 has come and gone, but the numerous abstracts and information presented will be built upon for many years to come. As a first time attendee to the ASH conference, I found it to be a very enriching experience. The abundance of information was overwhelming and seemed to be too much for me to […]

Recollections of the 60th Annual ASH Meeting and Expo

Jim Omel |

ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

ASH 2018: My Final Thoughts, Links, and Thanks!

Robin Tuohy |

While this year’s ASH had 939 abstracts about multiple myeloma, I agree with Linda Huguelet that this year was a building year, and no real blockbusters. However, and it’s a big however, because there are many future blockbusters expected from the early phase 1 trials as they continue forward, I encourage that you pay attention […]

Back To ‘Normal’ Life

Linda Huguelet |

Well, it’s 5:00 a.m. PT, although I keep telling myself that’s 8:00 a.m. ET, so it doesn’t seem so early. I’m at the San Diego airport waiting for my flight back home from the 2018 American Society of Hematology (ASH) annual meeting and exposition. It has been four, long, intense days of being totally immersed […]

Day 3 – Saving the Best for Last

Jack Aiello |

December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]

Snoopy Philosophy

John DeFlice |

CHARLIE BROWN:  Someday we will die, Snoopy. SNOOPY:  True, but all the other days, we will not. Snoopy’s philosophy resonates at ASH 2018 because of all the exciting information on immunotherapy.  There are new approaches to the use of daratumumab with other agents in quadruple combinations that result in high rate of response in newly […]

@MyelomaTeacher … #PatientsIncluded at #ASH18

Cynthia Chmielewski |

I am looking forward to shedding my puffy winter jacket and traveling to sunny San Diego to attend the 60th Annual Meeting of the American Society of Hematology (#ASH18) with the International Myeloma Foundation (IMF). This will be the seventh time I have attended ASH, but going to this meeting never gets old. I anxiously […]

How Do Patients Learn at ASH?

Jack Aiello |

Soon I’ll be off to San Diego, the site of this year’s American Society of Hematology (ASH) conference. ASH is all about blood cancers (leukemia, lymphoma, multiple myeloma), and there are nearly 700 oral presentations and posters on myeloma alone. I’m so grateful to the International Myeloma Foundation (IMF) and their sponsors for sending me, […]